FNY Managed Accounts LLC acquired a new position in Laboratory Corp. of America Holdings (NYSE:LH) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 1,500 shares of the medical research company’s stock, valued at approximately $239,000.

A number of other institutional investors have also recently bought and sold shares of LH. First Allied Advisory Services Inc. increased its position in shares of Laboratory Corp. of America by 2.6% during the second quarter. First Allied Advisory Services Inc. now owns 3,033 shares of the medical research company’s stock worth $462,000 after acquiring an additional 78 shares during the period. Sentry Investment Management LLC increased its holdings in Laboratory Corp. of America by 1.0% during the second quarter. Sentry Investment Management LLC now owns 7,756 shares of the medical research company’s stock valued at $1,196,000 after buying an additional 78 shares during the period. Stonebridge Capital Advisors LLC increased its holdings in Laboratory Corp. of America by 0.5% during the second quarter. Stonebridge Capital Advisors LLC now owns 19,855 shares of the medical research company’s stock valued at $3,060,000 after buying an additional 100 shares during the period. Profund Advisors LLC increased its holdings in Laboratory Corp. of America by 6.6% during the second quarter. Profund Advisors LLC now owns 4,370 shares of the medical research company’s stock valued at $674,000 after buying an additional 271 shares during the period. Finally, DnB Asset Management AS increased its holdings in Laboratory Corp. of America by 2.7% during the fourth quarter. DnB Asset Management AS now owns 11,474 shares of the medical research company’s stock valued at $1,830,000 after buying an additional 300 shares during the period. 90.98% of the stock is currently owned by institutional investors.

In other Laboratory Corp. of America news, Director Dwight Gary Gilliland sold 971 shares of the firm’s stock in a transaction that occurred on Monday, October 30th. The shares were sold at an average price of $153.52, for a total value of $149,067.92. Following the completion of the sale, the director now directly owns 3,501 shares in the company, valued at $537,473.52. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.90% of the stock is owned by company insiders.

Shares of Laboratory Corp. of America Holdings (NYSE:LH) traded up $1.87 on Tuesday, reaching $176.26. 302,400 shares of the company’s stock traded hands, compared to its average volume of 541,607. The firm has a market capitalization of $17,980.00, a P/E ratio of 24.58, a price-to-earnings-growth ratio of 1.66 and a beta of 0.87. Laboratory Corp. of America Holdings has a 52 week low of $128.00 and a 52 week high of $176.27. The company has a current ratio of 1.89, a quick ratio of 1.75 and a debt-to-equity ratio of 1.18.

Laboratory Corp. of America (NYSE:LH) last announced its earnings results on Wednesday, October 25th. The medical research company reported $2.46 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.38 by $0.08. The company had revenue of $2.60 billion during the quarter, compared to the consensus estimate of $2.55 billion. Laboratory Corp. of America had a net margin of 7.40% and a return on equity of 16.75%. Laboratory Corp. of America’s revenue was up 9.5% compared to the same quarter last year. During the same period last year, the firm earned $2.25 earnings per share. research analysts anticipate that Laboratory Corp. of America Holdings will post 9.53 earnings per share for the current fiscal year.

LH has been the topic of several research reports. SunTrust Banks reissued a “buy” rating and set a $190.00 price objective on shares of Laboratory Corp. of America in a report on Thursday, October 12th. Zacks Investment Research raised shares of Laboratory Corp. of America from a “hold” rating to a “buy” rating and set a $170.00 price objective on the stock in a report on Tuesday, October 10th. Deutsche Bank lifted their price objective on shares of Laboratory Corp. of America from $170.00 to $172.00 and gave the company a “buy” rating in a report on Thursday, October 26th. Craig Hallum reissued a “buy” rating and set a $180.00 price objective (up from $175.00) on shares of Laboratory Corp. of America in a report on Thursday, October 26th. Finally, ValuEngine raised shares of Laboratory Corp. of America from a “hold” rating to a “buy” rating in a report on Thursday, November 30th. Seven investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $171.69.

WARNING: This story was originally published by Daily Political and is owned by of Daily Political. If you are accessing this story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this story can be viewed at https://www.dailypolitical.com/2018/01/23/fny-managed-accounts-llc-invests-239000-in-laboratory-corp-of-america-holdings-lh-stock.html.

About Laboratory Corp. of America

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Laboratory Corp. of America Holdings (NYSE:LH).

Institutional Ownership by Quarter for Laboratory Corp. of America (NYSE:LH)

Receive News & Ratings for Laboratory Corp. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America and related companies with MarketBeat.com's FREE daily email newsletter.